Posted on 09/11/19
This report provides an overview of research and development of innovations for diagnosing, preventing, treating TB in children, and also includes some information about DR and MDR-TB in children as well. Access the PDF of the report here.
The 50th Union World Conference on Lung Health will be held from 30 October to 2 November 2019 in Hyderabad, India. RESIST-TB has summarized a list of symposia, oral abstracts, and workshops relating to drug-resistant tuberculosis (DR-TB) from the online programme in order to create this flyer.
Please view the flyer here!
Below is the most recent State of the Art article from IJTLD, which discusses the use of palliative care and symptom relief (PCSR) for people affected by MDR-TB.
1. Palliative care and symptom relief for people affected by multi-drug resistant tuberculosis
Below is the new 2019 Lancet tuberculosis series presenting how the diagnosis of MDR-TB can be improved, how drug regimens can best be used to treat and applied to different populations, and how MDR-TB can be managed in the future.
2. The Lancet Tuberculosis 2019
FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
Posted on 08/15/19
The FDA has approved a new drug for highly-resistant forms of drug-resistant tuberculosis. Developed by the non-profit TB alliance, Pretomanid has been approved to be used in a combination regimen with bedaquiline and linezolid for people with MDR-TB and XDR-TB.
Here are a few items that address the exciting news about the FDA approval of pretomanid in the BPaL regimen; describe concern about the standard of the research that led to its approval, the regulatory precedent it sets; and highlight uncertainty around its affordability and access.
1. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
2. New tuberculosis medicine studied in South Africa approved in United States
3. New Drug Could Be Game Changer For Drug-Resistant TB. But A Question Looms
1. NIH launches large TB prevention trial for people exposed to multidrug-resistant TB
A large clinical trial is being conducted to assess the treatments available for individuals who are at high-risk for developing multi-drug resistant tuberculosis (MDR-TB).
2. Management of patients with multidrug-resistant tuberculosis
Recommendations for the management of MDR-TB are discussed in this June issue of the State of the Art articles from IJTLD.
Posted on 08/07/19
The World Health Organization (WHO) is developing new guidelines for the treatment of drug-resistant TB (DR-TB) by issuing a public call appealing to industry, researchers, national TB programs, and other agencies to provide appropriate datasets.
Posted on 07/11/19
The first online consultation is being launched by the Stop TB Partnership in order to update the Global Plan to end TB 2016 – 2020. This will align the The Paradigm Shift with the UN Political Declaration on TB targets and commitments in the next three-year replenishment cycle of the Global Fund covering 2021 and 2022.
FDA Antimicrobial Drugs Advisory Committee recommends approval of pretomanid
Posted on 6/21/19
Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen. A decision regarding pretomanid approval is expected to be made by August of 2019.
For more news, click here.
The International Journal of Tuberculosis and Lung Disease has released its May publication featuring RESIST-TB Steering Committee Members C. Robert Horsburgh and Carole Mitnick as Guest Editors. This issue also features a supplemental publication by C. Robert Horsburgh and Amita Gupta titled, “MDR-TB in Children: Back to the Basics.”
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
To view the IJTLD May issue, click here.
To read “MDR-TB in Children: Back to the Basics,” click here.